Moderna completes construction of Canadian mRNA production site
The facility is anticipated to produce respiratory mRNA vaccines for Canadians in 2025 and improve domestic preparedness for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Feb 24
The facility is anticipated to produce respiratory mRNA vaccines for Canadians in 2025 and improve domestic preparedness for…
18 Jan 24
The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays,…
09 Jan 24
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand
05 Jan 24
The new four-story 20,000 m² facility will feature mammalian cell culture, messenger RNA and cell therapy services and…
19 Dec 23
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a…
04 Dec 23
The production facility is a GMP pilot plant that will help GC Biopharma achieve its goal of internalising…
27 Nov 23
With adherence to stringent international regulatory guidelines, the new facility at Pithampur marks a significant leap in manufacturing…
27 Oct 23
An ISO 7 cGMP Cleanroom Facility Grand Opening On October 26, 2023
20 Oct 23
The expansion project, part of the global investment plans announced in 2022, includes construction of a new extensive…
15 Sep 23
The investment is expected to expand Astellas’ capacity and capabilities for aseptic drug products in Ireland, strengthen stable…